- Home
- HSHP vs THRD Comparison
HSHP vs THRD Comparison
Compare HSHP & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSHP
- THRD
- Stock Information
- Founded
- HSHP 2021
- THRD 2019
- Country
- HSHP Bermuda
- THRD United States
- Employees
- HSHP N/A
- THRD N/A
- Industry
- HSHP
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- HSHP
- THRD Health Care
- Exchange
- HSHP Nasdaq
- THRD Nasdaq
- Market Cap
- HSHP 314.8M
- THRD 335.2M
- IPO Year
- HSHP 2023
- THRD 2022
- Fundamental
- Price
- HSHP $4.91
- THRD $6.00
- Analyst Decision
- HSHP
- THRD Strong Buy
- Analyst Count
- HSHP 0
- THRD 3
- Target Price
- HSHP N/A
- THRD $20.33
- AVG Volume (30 Days)
- HSHP 131.0K
- THRD 248.2K
- Earning Date
- HSHP 01-01-0001
- THRD 11-07-2024
- Dividend Yield
- HSHP 9.51%
- THRD N/A
- EPS Growth
- HSHP N/A
- THRD N/A
- EPS
- HSHP 0.57
- THRD N/A
- Revenue
- HSHP $112,303,000.00
- THRD N/A
- Revenue This Year
- HSHP $260.76
- THRD N/A
- Revenue Next Year
- HSHP $18.68
- THRD N/A
- P/E Ratio
- HSHP $8.69
- THRD N/A
- Revenue Growth
- HSHP 509.85
- THRD N/A
- 52 Week Low
- HSHP $4.54
- THRD $5.60
- 52 Week High
- HSHP $9.76
- THRD $16.94
- Technical
- Relative Strength Index (RSI)
- HSHP 40.74
- THRD 23.75
- Support Level
- HSHP $4.92
- THRD $5.60
- Resistance Level
- HSHP $5.24
- THRD $11.78
- Average True Range (ATR)
- HSHP 0.15
- THRD 0.89
- MACD
- HSHP 0.07
- THRD -0.43
- Stochastic Oscillator
- HSHP 31.35
- THRD 6.50
About HSHP Himalaya Shipping Ltd.
Himalaya Shipping Ltd is an independent dry bulk company that focuses on owning and operating its Newcastlemax dry bulk carriers.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.